Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Xenon Pharmaceuticals Inc (XENE)

$8.91 0.16 (1.83%)

16:00 EDT XENE Stock Quote Delayed 15 Minutes

Volume:

Previous Close -

Market Cap 156.92M

PE Ratio -5.94

EPS -1.5

Volume (Avg. Vol.) 15,300

Day's Range 8.80 - 9.19

52-Week Range 5.41 - 11.34

Dividend & Yield N/A (N/A)

XENE Stock Predictions, Articles, and Xenon Pharmaceuticals Inc News

From InvestorPlace
From the Web

Xenon Pharmaceuticals Inc (XENE) Plunges on Acne Drug Flop

By William White, InvestorPlace Writer Mar 24, 2017

Xenon Pharmaceuticals (XENE) stock was falling hard on Friday following results from a recent study of its acne drug XEN801.

Xenon Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for XENE

From Market News Video Oct 17, 2019

In trading on Thursday, shares of Xenon Pharmaceuticals Inc (XENE) crossed above their 200 day moving average of $9.14, changing hands as high as $9.19 per share. Xenon Pharmaceuticals Inc shares are currently trading up about 3.7% on the day..

Xenon Sees Hammer Chart Pattern: Time to Buy?

From Zacks Investment Research Oct 1, 2019

Xenon Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

What Did This CEO Just Do with Personal Shares of Xenon (NASDAQ: XENE)?

From Analyst Ratings Sep 24, 2019

Today, the CEO of Xenon (XENE – Research Report), Simon Pimstone, sold shares of XENE for $98.86K. Following Simon Pimstone’s last XENE Sell transaction on March 14, 2018, the stock climbed by 4.5%. In addition to Simon Pimstone, 3 other XENE executives reported Sell trades in the last month. See today’s analyst top recommended stocks

Benzinga's Top Upgrades, Downgrades For September 20, 2019

From Benzinga Sep 20, 2019

Upgrades Gordon Haskett changed the rating for Costco Wholesale Corp (NASDAQ: COST) from Hold to Accumulate. In the third quarter, Costco Wholesale showed an EPS of $1.89,...

Positive Developments for These 3 Biotech Stocks

From Real Money Sep 11, 2019

We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.

The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

From Benzinga Sep 10, 2019

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

C

Hold

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!